TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

AHA still working to find more patients with severe aortic stenosis who may require care
The initiative is designed to help identify more patients who may require aortic valve replacement. Brian Lindman, MD, provided an update on the project's efforts.
The biggest names in TAVR are sharing new data at ACC.25
The country’s two biggest TAVR vendors both plan on making a splash at ACC.25. Medtronic and Edwards Lifesciences spoke to Cardiovascular Business about their plans for the three-day event in Chicago.
New drug shows early potential to treat aortic stenosis in some patients without TAVR, SAVR
The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.
TAVR for failing surgical valves: Lessons learned from new 5-year data
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

TCT 2017: Frailty provides prognostic value for TAVR patients—but better risk scores are needed

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

5 topics to watch at TCT 2017

The 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium kicks off in Denver in less than two weeks. In preparation, Gregg W. Stone, MD, co-director of medical research and education at the Cardiovascular Research Foundation, provided some expected highlights of this year’s session Oct. 16 during a press briefing.

Boston Scientific’s TAVI system exceeds expectations in clinical trial

Boston Scientific’s transcatheter aortic valve implantation (TAVI) technology, the LOTUS Valve System, shows superiority to a similar platform made by a competitor in a new clinical trial.

Mitral Mysteries: Imagers Explore a New Frontier in Transcatheter Valve Replacement

Transcatheter aortic valve replacement offers valuable lessons that can be applied to its mitral valve counterpart, according to imagers on the frontlines for both techniques.

Same-day discharge for TAVR marks new procedural milestone

One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day, and they were discharge by that evening. It was an eyebrow-raising feat for a procedure that typically requires several days of hospitalization.

TAVR in low-risk patients holds steady at 2 years

Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery in low-risk patients with severe aortic stenosis, based on two-year results presented May 19 at EuroPCR in Paris.

Boston Scientific receives CE Mark for the new 25 mm Lotus Valve System

Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

Boston Scientific Lotus Valve System demonstrates strong performance and safety profile at six months

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

AHA still working to find more patients with severe aortic stenosis who may require care

The biggest names in TAVR are sharing new data at ACC.25

New drug shows early potential to treat aortic stenosis in some patients without TAVR, SAVR

TAVR for failing surgical valves: Lessons learned from new 5-year data

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients

Around the web